- 《Lancet Rheumatology》 被引量: 0发表: 2022年 The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation A subgroup of patients with severe COVID-19 suffers from progression to acute respiratory distress syndrome and multiorgan failure. These patients present ...